Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

Cited In for PubMed (Select 19671765)

1.

Streptococcus pneumoniae Induces Autophagy through the Inhibition of the PI3K-I/Akt/mTOR Pathway and ROS Hypergeneration in A549 Cells.

Li P, Shi J, He Q, Hu Q, Wang YY, Zhang LJ, Chan WT, Chen WX.

PLoS One. 2015 Mar 24;10(3):e0122753. doi: 10.1371/journal.pone.0122753. eCollection 2015.

2.

REACTIVE OXYGEN SPECIES AND COLORECTAL CANCER.

Sreevalsan S, Safe S.

Curr Colorectal Cancer Rep. 2013 Dec;9(4):350-357.

3.

Proteomic analysis of gossypol induces necrosis in multiple myeloma cells.

Xu R, Tian E, Tang H, Liu C, Wang Q.

Biomed Res Int. 2014;2014:839232. doi: 10.1155/2014/839232. Epub 2014 Aug 14.

4.

A preclinical assay for chemosensitivity in multiple myeloma.

Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS.

Cancer Res. 2014 Jan 1;74(1):56-67. doi: 10.1158/0008-5472.CAN-13-2397. Epub 2013 Dec 5.

5.

Combinatorial peptide libraries: mining for cell-binding peptides.

Gray BP, Brown KC.

Chem Rev. 2014 Jan 22;114(2):1020-81. doi: 10.1021/cr400166n. Epub 2013 Dec 3. Review. No abstract available.

6.

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.

Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM.

J Cancer. 2013 Sep 10;4(8):614-25. doi: 10.7150/jca.7080. eCollection 2013.

7.

MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.

Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA.

Mol Cancer Ther. 2013 Nov;12(11):2446-58. doi: 10.1158/1535-7163.MCT-13-0310. Epub 2013 Sep 18.

8.

Azacytidine induces necrosis of multiple myeloma cells through oxidative stress.

Tian E, Tang H, Xu R, Liu C, Deng H, Wang Q.

Proteome Sci. 2013 Jun 13;11(1):24. doi: 10.1186/1477-5956-11-24.

9.

DangER: protein ovERload. Targeting protein degradation to treat myeloma.

Aronson LI, Davies FE.

Haematologica. 2012 Aug;97(8):1119-30. doi: 10.3324/haematol.2012.064923. Epub 2012 May 11. Review.

10.

Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.

Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA.

Leuk Res. 2012 Jun;36(6):756-63. doi: 10.1016/j.leukres.2011.12.002. Epub 2011 Dec 30.

11.

Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy.

Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB.

Antioxid Redox Signal. 2012 Jun 1;16(11):1295-322. doi: 10.1089/ars.2011.4414. Epub 2012 Jan 16.

12.

Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH.

Yin L, Kosugi M, Kufe D.

Blood. 2012 Jan 19;119(3):810-6. doi: 10.1182/blood-2011-07-369686. Epub 2011 Nov 23.

13.

Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.

Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA.

Mol Cancer Ther. 2011 Dec;10(12):2257-66. doi: 10.1158/1535-7163.MCT-11-0149. Epub 2011 Oct 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk